Role of maximum androgen blockade in advanced prostate cancer

Role of maximum androgen blockade in advanced prostate cancer

Androgen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades, numerous...

Full description

Bibliographic Details
Main Authors:	Rajinikanth Ayyathurai, Rosely De Los Santos, Murugesan Manoharan
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2009-01-01
Series:	Indian Journal of Urology
Subjects:	Advanced prostate cancer maximum androgen blockade total androgen blockade
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2009;volume=25;issue=1;spage=47;epage=51;aulast=Ayyathurai

Similar Items

Maximal androgen blockade for advanced prostate cancer
by: Rajiv Paul Mukha, et al.
Published: (2010-01-01)

Therapeutic benefits of maximum androgen blockade and tolerability of bicalutamide in patients with advanced prostate cancer
by: A E Aghaji, et al.
Published: (2004-01-01)

Quality of life and results of total androgen blockade alone and with radiotherapy in the treatment of nonmetastatic prostate cancer
by: Milovanović Lela, et al.
Published: (2012-01-01)

Prolonged Remission of Prostate Cancer Presenting as Endobronchial Metastases Following Total Androgen Blockade: A Case Report and Literature Review
by: Robert S. Freund, et al.
Published: (2019-09-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
by: Yong Luo, et al.
Published: (2018-06-01)

Diagnosis and combined treatment of patients with locally advanced prostate cancer
by: Popkov V.M., et al.
Published: (2015-09-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Early report of randomized double blind clinical trial of hormonal therapy of carcinoma of prostate (CAP) stage D2
by: Jagdeesh N Kulkarni, et al.
Published: (2003-01-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade
by: Ning Wang, et al.
Published: (2019-01-01)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
by: Hideyuki Akaza
Published: (2013-06-01)

Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility
by: Fernand Labrie
Published: (2004-02-01)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
by: Katharina Lückerath, et al.
Published: (2018-10-01)

Testicular sperm extraction in a patient with ejaculatory dysfunction after combined androgen blockade therapy for prostate cancer
by: Toshiyasu Amano, et al.
Published: (2020-07-01)

Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
by: Nigel P Murray, et al.
Published: (2011-01-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
by: Frederico Leal, et al.
Published: (2015-06-01)

Effect of maximal androgen blockade therapy on hematological, biochemical and bone density in locally advanced prostate cancer
by: Erhan Demi̇relli̇, et al.
Published: (2018-11-01)

The role of 11-oxygenated androgens in prostate cancer
by: Gido Snaterse, et al.
Published: (2023-04-01)

Androgen Receptor Roles in Benign and Malignant Prostate Disease
Published: (2011-06-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer
by: Francisco Paulo da Fonseca, et al.

Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade
by: Vojinov Saša, et al.
Published: (2011-01-01)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
by: Mikio Sugimoto, et al.
Published: (2022-09-01)

Stromal Androgen Receptor in Prostate Cancer Development and Progression
by: Damien A. Leach, et al.
Published: (2017-01-01)

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
by: Sirin Saranyutanon, et al.
Published: (2019-12-01)

Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer
by: Katie Joanna Miller, et al.
Published: (2022-03-01)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
by: Daisuke Obinata, et al.
Published: (2023-04-01)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
by: Zoran Culig
Published: (2021-06-01)

Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer
by: Sean McSweeney, et al.
Published: (2023-01-01)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
by: Günel Huseynova, et al.
Published: (2022-12-01)

Androgens and prostate disease
by: Lori A Cooper, et al.
Published: (2014-04-01)

Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression
by: Ken-ichi Takayama, et al.
Published: (2017-08-01)

Hormonal Therapies for Patients with Advanced Prostate Cancer
by: Cora N. Sternberg, et al.
Published: (2016-01-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
by: Haozhe Zhang, et al.
Published: (2022-11-01)

Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
by: Eva Estébanez-Perpiñá, et al.
Published: (2021-01-01)

The role of cyclins in the development and progression of prostate cancer
by: Joanna Dulińska-Litewka, et al.
Published: (2022-11-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)